The Janus kinase (JAK) inhibitor upadacitinib provides early and durable reductions in axial spondyloarthritis (axSpA) pain, with links to long-term disease control outcomes, according to a recent post hoc analysis of key phase 2/3 trials.
Pain remains a dominant and